Vidarbha News

Seborrhoeic Dermatitis Pipeline Report Analysis by DelveInsight

 Breaking News
  • No posts were found

Seborrhoeic Dermatitis Pipeline Report Analysis by DelveInsight

September 20
14:29 2021
Seborrhoeic Dermatitis Pipeline Report Analysis by DelveInsight
Seborrhoeic Dermatitis Pipeline
Currently, 5+ companies and 5+ pipeline drugs are in the Seborrhoeic Dermatitis pipeline landscape.

DelveInsight’s Seborrhoeic Dermatitis pipeline report provides comprehensive coverage of the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

Some of the Key Highlights from the Seborrhoeic Dermatitis Pipeline Report

  • There are currently 5+ drugs in the Seborrhoeic Dermatitis pipeline.

  • The Seborrhoeic Dermatitis pipeline comprises therapies in different clinical phase stages, including ARQ-154, DBI-002, PAC 14028, MSB-7154, and others.

  • Some of the companies actively working to improve the Seborrhoeic Dermatitis treatment landscape are Arcutis Biotherapeutics, Inc., DermBiont, Amorepacific, MatriSys Bio, and others.

  • Seborrhoeic Dermatitis pipeline therapies that are in the late stage of development include ARQ-154 (Arcutis Biotherapeutics), DBI-002 (DermBiont), PAC 14028 (Amorepacific), along with others.

  • MSB-7154 is being developed and investigated in the preclinical stage by MatriSys Bio.

Get a detailed analysis of the pipeline landscape @ Seborrhoeic Dermatitis Pipeline Analysis

Seborrhoeic Dermatitis Overview

Seborrhoeic Dermatitis, also known as seborrhoea, is a chronic skin condition. It is a skin condition distinguished by scaly patches and red skin, most notably on the scalp. Seborrhoea can also occur on oily body parts such as the face, sides of the nose, brows, ears, eyelids, upper chest, and back. Seborrhoeic dermatitis can cause stubborn dandruff in addition to scaly patches and red skin.

Seborrhoeic Dermatitis Symptoms

Seborrheic Dermatitis symptoms include:

  • Dandruff (skin flakes) on your scalp, hair, brows, beard, or mustache

  • Patches of greasy skin with flaky white or yellow scales or crust on the scalp, face, sides of the nose, brows, ears, eyelids, chest, armpits, groin area, or under the breasts.

  • Red skin

  • Itching

Seborrhoeic Dermatitis Treatment

The main options for Seborrheic Dermatitis treatments are medicated shampoos, creams, and lotions. Before turning to prescription medications, dermatologists advise patients to try home remedies first, such as over-the-counter dandruff shampoos.

Seborrhoeic Dermatitis Pipeline Analysis: Drug Profiles

ARQ-154: Arcutis Biotherapeutics, Inc.

Product Description

ARQ-154, or topical roflumilast foam, is a foam formulation of a highly potent and selective PDE4 inhibitor (roflumilast). Roflumilast has been licensed by the US Food and Drug Administration (FDA) for systemic use to lower the risk of COPD exacerbations since 2011.

Phase III

NCT04973228: Arcutis Biotherapeutics, Inc. began a randomized, Phase III trial in July 2021 to assess the efficacy and safety of ARQ-154 Foam 0.3 percent Administered QD in subjects with Seborrheic Dermatitis.

Seborrhoeic Dermatitis Pipeline Therapies and Key Companies

  • ARQ-154: Arcutis Biotherapeutics, Inc.

  • DBI-002: DermBiont

  • PAC 14028: Amorepacific

  • MSB-7154: MatriSys Bio

Find out the emerging therapies and companies @ Seborrhoeic Dermatitis Treatment 

Seborrhoeic Dermatitis Therapeutics Assessment

  • By Product Type

    • Monotherapy

    • Combination Therapy

  • By Stage

    • Discovery

    • Pre-Clinical

    • Phase I

    • Phase II

    • Phase III

    • Pre-registration

  • By Route of Administration

    • Inhalation

    • Intravenous

    • Oral

    • Subcutaneous

  • By Molecule Type

    • Small Molecule

    • Stem Cell Therapy

    • Gene Therapy

  • Targets

    • Immune System

    • Multiple Kinase

  • By Mechanism of Action

    • Protease Inhibitors

    • Immunomodulatory

Scope of the Report

Coverage: Global

Seborrhoeic Dermatitis Key Players: Arcutis Biotherapeutics, Inc., DermBiont, Amorepacific, MatriSys Bio, among others

Seborrhoeic Dermatitis Pipeline Therapies: ARQ-154, DBI-002, PAC 14028, MSB-7154, and others

Table of Contents




Executive Summary


Seborrhoeic Dermatitis: Overview


Seborrhoeic Dermatitis- Analytical Perspective In-depth Commercial Assessment


Seborrhoeic Dermatitis Pipeline Therapeutics


Seborrhoeic Dermatitis Late Stage Products (Phase III)


Seborrhoeic Dermatitis Mid Stage Products (Phase II)


Seborrhoeic Dermatitis Early Stage Products (Phase I)


Seborrhoeic Dermatitis Preclinical Products


Seborrhoeic Dermatitis Therapeutic Assessment


Seborrhoeic Dermatitis Inactive Products


Seborrhoeic Dermatitis Company-University Collaborations (Licensing/Partnering) Analysis


Seborrhoeic Dermatitis Key Companies


Seborrhoeic Dermatitis Key Products


Seborrhoeic Dermatitis- Unmet Needs


Seborrhoeic Dermatitis- Market Drivers and Barriers


Seborrhoeic Dermatitis- Future Perspectives and Conclusion


Seborrhoeic Dermatitis Analyst Views




About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Key questions answered in the Seborrhoeic Dermatitis Pipeline Report

  • What treatments are available for seborrhoeic dermatitis?

  • How many pharmaceutical companies are developing Seborrhoeic Dermatitis treatments?

  • Which of these firms’ pharmaceuticals is the most widely used?

  • How many Seborrhoeic Dermatitis medications is each company producing?

  • How many drugs for Seborrheic Dermatitis are in the early, mid, or late stages of development?

  • How many of the current therapies under development can be used alone or in combination with other treatments?

  • What are the essential industry-industry and industry-academy collaborations, mergers and acquisitions, and licensing practices affecting seborrhoeic dermatitis?

Related Reports

Sebohrrea Pipeline Insights

Get a comprehensive analysis of Sebohrrea pipeline therapies and key companies, including Arcutis Biotherapeutics, Cutanea Life Sciences Inc., Vyome Therapeutics, among others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States